Quick Answer
OS Therapies Inc reported Research And Development Expense of $16.36 million for the year ending 2025.
- OS Therapies Inc showed an increase of +476.3% in Research And Development Expense from 2024 to 2025.
- This data is from OS Therapies Inc's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $753.8 thousand | Q2 2023: $992.9 thousand | Q3 2023: $454.5 thousand | Q1 2024: $361.8 thousand | Q2 2024: $396.6 thousand | Q3 2024: $1.21 million | Q1 2025: $1.31 million | Q2 2025: $2.50 million | Q3 2025: $3.76 million.
- Over the full 3 years of available data (2023 to 2025), OS Therapies Inc's Research And Development Expense has grown by 408.6%.
- Historical annual values: Fiscal year 2025: $16.36 million | Fiscal year 2024: $2.84 million | Fiscal year 2023: $3.22 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: